Brain Computer Implants Articles & Analysis
13 news found
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Surgeons at Intermountain Primary Children’s Hospital are the first in the nation to successfully implant a new brain shunt accessory for young patients with hydrocephalus, a neurological condition that causes a buildup of cerebrospinal fluid in the deep cavities of the brain that often causes frequent hospitalizations. This extra fluid puts pressure on the brain and can cause brain ...
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. ...
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. ...
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of ...
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. ...
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. The current standard of care for patients with ...
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. ...
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
NDI Medical, LLC, a venture and commercialization firm that funds and develops innovative neurodevice technologies, has launched its next portfolio company, Deep Brain Innovations, LLC (DBI). DBI will commercialize its groundbreaking technology that is designed to optimize deep brain stimulation (DBS) therapy for patients with Parkinson’s disease. ...